Jessica Mendoza
👤 SpeakerVoice Profile Active
This person's voice can be automatically recognized across podcast episodes using AI voice matching.
Appearances Over Time
Podcast Appearances
New fears of a possible recession on the horizon, the Dow losing 876 points after falling.
New fears of a possible recession on the horizon, the Dow losing 876 points after falling.
New fears of a possible recession on the horizon, the Dow losing 876 points after falling.
In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?
In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?
In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?
Tell me about the company behind this blockbuster drug.
Tell me about the company behind this blockbuster drug.
Tell me about the company behind this blockbuster drug.
Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.
Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.
Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.
Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.
Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.
Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.
By leaving, do we mean he's resigning? Is he retiring? What's going on?
By leaving, do we mean he's resigning? Is he retiring? What's going on?
By leaving, do we mean he's resigning? Is he retiring? What's going on?
Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Wednesday, May 21st. Coming up on the show, Ozempic is a huge hit. So why is the drugmaker's CEO out? For most of its hundred-year history, Novo Nordisk was known mainly as a maker of insulin.
Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Wednesday, May 21st. Coming up on the show, Ozempic is a huge hit. So why is the drugmaker's CEO out? For most of its hundred-year history, Novo Nordisk was known mainly as a maker of insulin.